The 'arginine paradox' in cardiomyocytes is mediated by millimolar L-arginine acting as an agonist of alpha2-adrenoceptors to inhibit L-type Ca2+ channels, a mechanism that is impaired in spontaneously hypertensive rats.
L-arginine effects on Ca2+ currents are impaired in hypertensive rat cardiomyocytes; leaves open relevance of the arginine paradox to human hypertension.
The “arginine paradox” in cardiomyocytes isolated from the left ventricle of Spraque Dawlay (SD) and spontaneously hypertensive rats (SHR) was studied. With 1 mM L -arginine in the bath, the addition of 5 mM L -arginine to incubation medium increased NO production and inhibited amplitude of L-type Ca 2+ currents in SD cardiomyocytes. A variety of compounds, including the antagonist of α 2 -adrenoceptors yohimbine and inhibitors of PI3 kinase (wortmanine), NO synthase (7NI), and cGMP-dependent protein kinase (KT5823), dramatically weakened the inhibitory effects of 5 mM L -arginine on Ca 2+ currents. The agonist of α 2 -adrenoceptors guanabenz acetate increased NO production and inhibited Ca 2+ currents, while wortmanine, 7NI, and KT5823 antagonized guanabenz. In SHR cardiomyocytes, the “arginine paradox” was not observed: 5 mM L -arginine affected neither NO production nor Ca 2+ currents. Consistently, guanabenz acetate did not alter NO production and inhibited Ca 2+ currents to a much smaller extent in SHR cardiomyocytes as compared to SD cardiomyocytes. Taken together, the data of the inhibitory analysis suggest that millimolar L -arginine serves as an agonist of α 2 -adrenoceptors, which are coupled to PI3K-Akt pathway as well as downstream NO-cGMP pathway to control activity of L-type Ca 2+ channels, thus providing new insights into the “arginine paradox” in cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Nenov et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: